Q3 2024 Biogaia AB Earnings Call Transcript
This is Theresa Agnew, CEO of BioGaia. I want to do an overview of our results for Q3. First off, our sales were SEK 304 million which was a decline of 4% mainly due to weaker sales in EMEA as well as some order variability. Where we had higher orders in Q2 in certain markets, sales in Europe, Middle East Africa decreased by 27%. And in Asia Pacific sales increased by 24%. And in the Americas, we had an increase of 5%. So good growth in Asia Pacific and also solid growth in the Americas. Our EBIT was SEK 41 million which was a decline of 65%. This was primarily due to an impairment loss that we had, which I will talk about our EBIT margin because of that was 14% without the impairment loss. If you look at the adjusted EBIT margin, it was 31% and the adjusted EBIT was SEK 93 million or a decline of 22%. So there were items that affected the comparability in the quarter. It was primarily an impairment loss attributed to our metabogen acquisition. And that impairment loss was SEK 51.2 million. And I will talk a little bit about the clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |